Analysts' Actions: JNPR ADSK CMI DVN CNQR

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Autodesk ( ADSK) downgraded at Jefferies to Hold from Buy, Jefferies said. $34 price target. Weaker data and limited uplift from suites. Hold rating.

Adtran ( ADTN) upgraded at Mizuho to Buy, Mizuho said. $22 price target. Business will likely bottom out in the fourth quarter.

Cummins ( CMI) upgraded at BMO from Market Perform to Outperform, BMO Capital said. $120 price target. Global growth appears to be stabilizing.

Concur ( CNQR) downgraded at Piper from Neutral to Underweight, Piper Jaffray said. Valuation call, based on a $49 price target.

Devon Energy ( DVN) downgraded at UBS to Neutral from Buy, UBS said. $60 price target. Long term outlook dims.

Devon Energy downgraded at Citigroup. DVN was downgraded to Neutral from Buy, Citigroup said. $62 price target. Lower costs, but reining in production growth outlook.

Exelon ( EXC) upgraded at UBS to Neutral from Sell, UBS said. $30 price target. Shares now reflect a lower dvidend.

FirstMerit ( FMER) upgraded at Baird from Underperform to Neutral, Robert Baird said. Valuation call, based on a $13 price target.

Health Net ( HNT) upgraded at BMO from Underperform to Market Perform, BMO Capital said. $23 price target. Near-term visibility is improving.

Juniper ( JNPR) upgraded at Cantor from Hold to Buy, Cantor Fitzgerald said. $21 price target. Company is cutting costs and is leveraged to higher carrier spending.

Linear Technology ( LLTC) upgraded at UBS to Buy from Neutral, UBS said. $38 price target. Improved relative growth rate supports raised valuation.

Universal Display ( PANL) downgraded at Wedbush from Outperform to Neutral, Wedbush said. $20 price target. Estimates also cut, as the company has reduced visibility.

Parker Hannifin ( PH) upgraded at BMO to Outperform, BMO Capital said. Valuation call, based on a $94 price target.

Perrigo ( PRGO) downgraded at Caris from Buy to Above Average, Caris & Co. said. $129 price target. Company is seeing slower demand for consumer healthcare and nutritionals.

PSS World Medical ( PSSI) downgraded at UBS to Neutral from Buy, UBS said. $29 price target. 10Q reveals inline results.

If you liked this article you might like

Cisco Could Be in Line for Some Big Changes With John Chambers' Exit

7 Essential Rules for Investing in Tech Stocks

John Chambers' Exit From Cisco Could Pave the Way for Big Moves

Why Intel, Nvidia and Others Are Seeing Their Sales to Cloud Giants Soar

After Cisco's Dive Drags Tech, Here's What Wall Street's Top Analyst Had to Say